A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

(2020) Luciano J. Costa et al.   BLOOD

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

(2020) Wenhua Liang et al.   LANCET ONCOLOGY

Multiple Myeloma in the Time of COVID-19

(2020) Abdullah S. Al Saleh et al.   ACTA HAEMATOLOGICA

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

(2020) L. Zhang et al.   ANNALS OF ONCOLOGY

Myeloma CAR-T CRS Management with IL-1R Antagonist Anakinra

(2020) Shashidhar S. Jatiani et al.   Clinical Lymphoma Myeloma & Leukemia

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

(2020) Chi Zhang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

(2020) Yang Cao et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

(2020) Hanren Dai et al.   Journal of Hematology & Oncology

Unequal Distribution of COVID‐19 Risk among Rural Residents by Race and Ethnicity

(2020) Carrie Henning‐Smith et al.   JOURNAL OF RURAL HEALTH

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak

(2020) Mengyuan Dai et al.   Cancer Discovery

Management of patients with multiple myeloma during the COVID-19 pandemic

(2020) Florent Malard et al.   Lancet Haematology

KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis

(2018) Ming Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cytokine release syndrome: grading, modeling, and new therapy

(2018) Delong Liu et al.   Journal of Hematology & Oncology

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals

(2018) Douglas G. Widman et al.   PLoS One

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immune Therapies in Multiple Myeloma

(2016) Shaji K. Kumar et al.   CLINICAL CANCER RESEARCH

Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study

(2016) Rasmus Sørrig et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Racial Differences in the Incidence of Cardiovascular Risk Factors in Older Black and White Adults

(2016) George Howard et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD